Q2 2025 EPS Estimates for Blueprint Medicines Co. (NASDAQ:BPMC) Boosted by Zacks Research

Blueprint Medicines Co. (NASDAQ:BPMC) – Research analysts at Zacks Research lifted their Q2 2025 earnings per share estimates for Blueprint Medicines in a report released on Wednesday, October 9th. Zacks Research analyst A. Chakraborty now expects that the biotechnology company will post earnings of ($0.78) per share for the quarter, up from their previous forecast of ($0.79). The consensus estimate for Blueprint Medicines’ current full-year earnings is ($3.99) per share. Zacks Research also issued estimates for Blueprint Medicines’ Q3 2025 earnings at ($0.58) EPS, FY2025 earnings at ($2.54) EPS, Q1 2026 earnings at ($0.45) EPS, Q3 2026 earnings at ($0.08) EPS and FY2026 earnings at $0.01 EPS.

Blueprint Medicines (NASDAQ:BPMC) last released its quarterly earnings results on Thursday, August 1st. The biotechnology company reported ($0.80) EPS for the quarter, beating the consensus estimate of ($1.29) by $0.49. The business had revenue of $138.20 million for the quarter, compared to analysts’ expectations of $104.02 million. Blueprint Medicines had a negative net margin of 56.64% and a negative return on equity of 157.30%. Blueprint Medicines’s revenue was up 139.9% compared to the same quarter last year. During the same period in the prior year, the firm earned ($2.19) earnings per share.

A number of other equities analysts have also recently issued reports on BPMC. Baird R W upgraded Blueprint Medicines to a “strong-buy” rating in a report on Friday, August 2nd. Robert W. Baird boosted their price objective on shares of Blueprint Medicines from $112.00 to $127.00 and gave the company an “outperform” rating in a research report on Friday, August 2nd. Barclays upped their price objective on Blueprint Medicines from $75.00 to $105.00 and gave the stock an “equal weight” rating in a research report on Monday, July 29th. Oppenheimer boosted their target price on shares of Blueprint Medicines from $114.00 to $125.00 and gave the stock an “outperform” rating in a research note on Monday, July 8th. Finally, Guggenheim lifted their price target on Blueprint Medicines from $130.00 to $138.00 and gave the company a “buy” rating in a research note on Friday, August 2nd. One analyst has rated the stock with a sell rating, six have assigned a hold rating, eleven have assigned a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $120.00.

Blueprint Medicines Stock Performance

Shares of BPMC stock opened at $88.81 on Monday. The stock has a 50-day moving average of $90.94 and a 200-day moving average of $99.05. The company has a debt-to-equity ratio of 1.06, a current ratio of 3.71 and a quick ratio of 3.65. The stock has a market cap of $5.56 billion, a PE ratio of -18.46 and a beta of 0.58. Blueprint Medicines has a one year low of $43.89 and a one year high of $121.90.

Insider Activity

In related news, insider Philina Lee sold 41,913 shares of the stock in a transaction that occurred on Monday, August 5th. The shares were sold at an average price of $93.19, for a total transaction of $3,905,872.47. Following the transaction, the insider now owns 34,729 shares in the company, valued at $3,236,395.51. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In related news, insider Philina Lee sold 41,913 shares of the stock in a transaction dated Monday, August 5th. The stock was sold at an average price of $93.19, for a total transaction of $3,905,872.47. Following the completion of the sale, the insider now owns 34,729 shares in the company, valued at approximately $3,236,395.51. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Fouad Namouni sold 3,633 shares of the business’s stock in a transaction on Thursday, October 3rd. The stock was sold at an average price of $89.32, for a total transaction of $324,499.56. Following the completion of the sale, the insider now owns 69,070 shares in the company, valued at $6,169,332.40. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 4.21% of the company’s stock.

Hedge Funds Weigh In On Blueprint Medicines

Several hedge funds have recently modified their holdings of the stock. Triad Wealth Partners LLC acquired a new stake in shares of Blueprint Medicines in the second quarter valued at about $27,000. Covestor Ltd lifted its holdings in Blueprint Medicines by 9,700.0% during the 1st quarter. Covestor Ltd now owns 294 shares of the biotechnology company’s stock worth $28,000 after buying an additional 291 shares in the last quarter. Headlands Technologies LLC increased its holdings in Blueprint Medicines by 105.2% during the 1st quarter. Headlands Technologies LLC now owns 667 shares of the biotechnology company’s stock worth $63,000 after purchasing an additional 342 shares during the period. Natixis purchased a new position in shares of Blueprint Medicines in the 1st quarter valued at about $73,000. Finally, CWM LLC boosted its stake in Blueprint Medicines by 114.6% in the second quarter. CWM LLC now owns 1,105 shares of the biotechnology company’s stock valued at $119,000 after acquiring an additional 590 shares in the last quarter.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.